Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension

Mark Toshner, Colin Church, Lars Harbaum, Christopher Rhodes, Sofia S. Villar Moreschi, James Liley, Rowena Jones, Amit Arora, Ken Batai, Ankit A. Desai, John G. Coghlan, J. Simon R. Gibbs, Dee Gor, Stefan Gräf, Louise Harlow, Jules Hernandez-Sanchez, Luke S. Howard, Marc Humbert, Jason Karnes, David G. Kiely, Rick Kittles, Emily Knightbridge, Brian Lam, Katie A. Lutz, William C. Nichols, Michael W. Pauciulo, Joanna Pepke-Zaba, Jay Suntharalingam, Florent Soubrier, Richard C. Trembath, Tae-Hwi L. Schwantes-An, S. John Wort, Martin R. Wilkins, Sean Gaine, Nicholas W. Morrell, Paul A. Corris the Uniphy Clinical Trials Network
European Respiratory Journal 2022 59: 2002463; DOI: 10.1183/13993003.02463-2020
Mark Toshner
1Dept of Medicine, University of Cambridge, Cambridge, UK
2Royal Papworth Hospital, Cambridge, UK
20Authors contributed equally to this work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark Toshner
  • For correspondence: mrt34@medschl.cam.ac.uk
Colin Church
3Golden Jubilee Hospital, Glasgow, UK
20Authors contributed equally to this work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Harbaum
4Heart Lung Research Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Rhodes
4Heart Lung Research Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sofia S. Villar Moreschi
5MRC Biostatistical Unit, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Liley
1Dept of Medicine, University of Cambridge, Cambridge, UK
5MRC Biostatistical Unit, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rowena Jones
1Dept of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit Arora
6Dept of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Batai
7Dept of Urology, University of Arizona, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ankit A. Desai
8Dept of Medicine, Indiana University, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John G. Coghlan
9Royal Free Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Simon R. Gibbs
4Heart Lung Research Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dee Gor
10Roche Products Limited, Welwyn Garden City, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Gräf
1Dept of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stefan Gräf
Louise Harlow
2Royal Papworth Hospital, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jules Hernandez-Sanchez
10Roche Products Limited, Welwyn Garden City, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luke S. Howard
4Heart Lung Research Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Luke S. Howard
Marc Humbert
11Université Paris-Sud, Le Kremlin-Bicêtre, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Humbert
Jason Karnes
6Dept of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David G. Kiely
12Royal Hallamshire Hospital, Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David G. Kiely
Rick Kittles
6Dept of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Knightbridge
1Dept of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Lam
13Institute of Metabolic Sciences, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katie A. Lutz
14Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William C. Nichols
14Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael W. Pauciulo
14Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanna Pepke-Zaba
2Royal Papworth Hospital, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jay Suntharalingam
15Royal United Hospital, Bath, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florent Soubrier
16Sorbonne Universités, INSERM, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Florent Soubrier
Richard C. Trembath
17Genetics and Molecular Medicine, King's College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tae-Hwi L. Schwantes-An
8Dept of Medicine, Indiana University, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. John Wort
4Heart Lung Research Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin R. Wilkins
4Heart Lung Research Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martin R. Wilkins
Sean Gaine
18Mater Misericordiae University Hospital, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas W. Morrell
1Dept of Medicine, University of Cambridge, Cambridge, UK
21Authors contributed equally to this work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul A. Corris
19Dept of Medicine, Newcastle University, Newcastle, UK
21Authors contributed equally to this work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background Inflammation and dysregulated immunity are important in the development of pulmonary arterial hypertension (PAH). Compelling preclinical data supports the therapeutic blockade of interleukin-6 (IL-6) signalling.

Methods We conducted a phase 2 open-label study of intravenous tocilizumab (8 mg·kg−1) over 6 months in patients with group 1 PAH. Co-primary end-points were safety, defined by incidence and severity of adverse events, and change in pulmonary vascular resistance. Separately, a mendelian randomisation study was undertaken on 11 744 individuals with European ancestry including 2085 patients with idiopathic/heritable disease for the IL-6 receptor (IL6R) variant (rs7529229), known to associate with circulating IL-6R levels.

Results We recruited 29 patients (male/female 10/19; mean±sd age 54.9±11.4 years). Of these, 19 had heritable/idiopathic PAH and 10 had connective tissue disease-associated PAH. Six were withdrawn prior to drug administration; 23 patients received at least one dose of tocilizumab. Tocilizumab was discontinued in four patients owing to serious adverse events. There were no deaths. Despite evidence of target engagement in plasma IL-6 and C-reactive protein levels, both intention-to-treat and modified intention-to-treat analyses demonstrated no change in pulmonary vascular resistance. Inflammatory markers did not predict treatment response. Mendelian randomisation did not support an effect of the lead IL6R variant on risk of PAH (OR 0.99, p=0.88).

Conclusion Adverse events were consistent with the known safety profile of tocilizumab. Tocilizumab did not show any consistent treatment effect.

Abstract

Tocilizumab did not block IL-6 signalling in pulmonary arterial hypertension. Multicentre mendelian randomisation studies additionally did not demonstrate evidence for IL-6R in pulmonary arterial hypertension. https://bit.ly/3xkDxS5

Introduction

Pulmonary arterial hypertension (PAH) is a rare and often fatal disease characterised by profound remodelling of small pulmonary arteries leading to increased pulmonary vascular resistance (PVR) and right heart failure [1]. Despite existing treatments, mortality remains high and there is a major unmet medical need to identify new therapies. Much interest has focused on the association of PAH with dysregulated immunity, infection and inflammation [2]. Autoimmune diseases are causative in PAH, most commonly scleroderma and systemic lupus erythematosus (SLE). In addition, inflammatory/infectious processes such as HIV infection and schistosomiasis are associated with PAH [3]. Idiopathic and heritable forms of PAH are also associated with autoimmune thyroid disease and human leukocyte antigen subtypes, and the presence of autoantibodies has been noted in up to 93% of patients [4]. Indeed, it has been proposed that idiopathic PAH might be an autoimmune disease [2].

Within the pulmonary vascular lesions of PAH, there is an accumulation of inflammatory cells, including T- and B-lymphocytes with altered regulatory T-cell function [5] and changes in B-cell gene expression [6]. However, it remains unclear whether these findings are a cause or a consequence of disease, e.g. caused by exposure to new antigens as a consequence of endothelial damage. One pathway with strong preclinical evidence for a central role in PAH is the interleukin-6 (IL-6) pathway. IL-6 levels are consistently elevated in peripheral blood and within the lung in PAH patients [7]. IL-6 is an independent marker of prognosis, outperforming traditional markers such as PVR and N-terminal pro-brain natriuretic peptide (NT-proBNP) [8]. Increased plasma IL-6 levels and association with the IL-6 receptor (IL-6R) risk alleles are reported in connective tissue diseases (CTDs) known to cause pulmonary hypertension, such as rheumatoid arthritis (RA) [9]. Transgenic overexpression of IL-6 in animal models promotes pulmonary hypertension [10]; conversely, IL-6-deficient mice are protected from hypoxia-induced pulmonary hypertension [11]. Administration of recombinant IL-6 to rats also recapitulates a PAH phenotype [12].

Tocilizumab is an IL-6R antagonist established as safe and effective, primarily in RA [13], and has shown promise in scleroderma [14]. IL-6R antagonism attenuates murine PAH and recent data suggest that ectopic IL-6 signalling directly drives vascular changes in animal models [15]. The rationale for inhibiting IL-6 signalling extends to the direct effects of IL-6 on vascular remodelling in addition to immunomodulation. Isolated case reports have suggested regression of PAH with tocilizumab in associated SLE, mixed CTD and Castleman's disease [16, 17].

We conducted a phase 2 open-label single-arm proof-of-concept study of tocilizumab in PAH. In parallel, we performed a mendelian randomised (MR) case–control study using a single nucleotide polymorphism (SNP) (rs7529229) in IL-6R to infer a causal relationship between IL-6R levels and risk in PAH. This SNP marks a protein quantitative trait locus for circulating IL-6R and includes, in high linkage disequilibrium, a non-synonymous variant (rs8192284) increasing the proteolytic cleavage of the soluble IL-6R from its membrane-bound form [18].

Methods

Study design and participants

Patients were recruited across eight centres in the UK (supplementary material) to an open-label single-arm study. The study (TRANSFORM-UK, ClinicalTrials.gov number NCT02676947) [19] was approved by the local research ethics committee (Leicester Central 15/EM/0401).

Patients on stable therapy aged 18–70 years with a diagnosis of group 1 PAH were enrolled: specifically, idiopathic or heritable PAH and PAH associated with CTD excluding SLE, RA and mixed CTD. Selected exclusion criteria included subjects on continuous intravenous (i.v.) or subcutaneous prostacyclin infusions, active infection, peripheral blood platelets <100×109 cells·L−1, neutrophil count <2×109 cells·L−1, concomitant treatment with biologics, evidence of coronary artery and left heart disease, total lung capacity ≤60% of predicted, forced expiratory volume in 1 s ≤60% of predicted and a 6-min walk test (6MWT) distance <100 m (full inclusion/exclusion criteria can be found in the supplementary material). All participants provided written informed consent.

Procedures

Participants were given i.v. tocilizumab monthly (8 mg·kg−1; Roche Pharmaceuticals) for 6 months on day 1 and weeks 4, 8, 12, 16 and 20 (six doses). Patients attended monthly for infusions and safety data collection. Worsening of PAH was defined by the occurrence of three of the following: a decrease in the 6MWT distance of at least 15% from baseline; the need for additional treatment for PAH; and the worsening of symptoms of PAH, including at least one of a change from baseline to a higher World Health Organization (WHO) functional class and the appearance or worsening of signs of right heart failure unresponsive to oral diuretic therapy. Peripheral blood sampling was undertaken at trial baseline and end of study. Blood was collected for flow cytometric evaluation of leukocyte subsets, RNA sequencing (RNAseq) and serum mediators of inflammation (C-reactive protein (CRP), IL-1β, IL-6, IL-8 and tumour necrosis factor-α (TNF-α)) (supplementary figure S1). Blood was collected in citrate phosphate dextrose adenine and processed within 30 min of sampling after transfer to a lymphocyte separation tube (EZ Lympho-Sep), which was centrifuged as per manufacturer instructions. After a red cell lysis step, peripheral blood mononuclear cells were separated, resuspended in PBS+2 mM EDTA, stored overnight at −80°C and transferred to liquid nitrogen. Immunophenotyping was undertaken on a Fortessa flow cytometer (BD Biosciences). Optimised combinations of primary antibodies were developed based on those proposed by the Human Immunophenotyping Consortium [20]. A minimum of 1×106 events was collected for each analyte. Blood was also processed for cytokine assay in serum separator tubes and Tempus Blood RNA Tubes (3 mL of blood per tube, Thermo Fisher Scientific). Samples were stored at −80°C until completion of the trial. Cytokines were measures from serum samples using a Meso Scale Discovery VPLEX multispot assay platform on the Meso Sector S600 analyser (MSD). Samples were prepared and analysed as per manufacturer instructions (MSD Human Proinflammatory Panel 1- K15049D). RNA extraction was performed using the Tempus Spin RNA Isolation Kit (Thermo Fisher Scientific) and included the optional DNase treatment step using AbsoluteRNA Wash Solution (Thermo Fisher Scientific) in accordance with manufacturer's protocol. Extracted RNA was then concentrated using RNeasy Minelute columns (Qiagen) and eluted in a final volume of 14 μL before depletion of globin mRNA using GLOBINclear (Thermo Fisher Scientific). Final elution of globin-depleted RNA was in 30 μL RNase-free water. The yield and RNA integrity score (RIN) of the samples was determined using the Eukaryote Total RNA Nano Chip Kit (Agilent Technologies) and run on an Agilent 2100 Bioanalyzer (Agilent Technologies); RIN numbers were calculated using the 2100 Expert Software (Agilent Technologies). Libraries for cDNA were prepared with the TruSeq Stranded mRNA Library Prep Kit (Illumina), which generates Poly-A-enriched strand-specific libraries. 1 μg of high-quality RNA was inputted and all protocols were performed following the manufacturer's instructions. Completed libraries were assessed by DNA 1000 Chip (Agilent Biotechnologies) on an Agilent 2100 Bioanalyzer (Agilent Biotechnologies) before normalisation and pooling. Pooled indexed libraries were submitted at 10 nM and sequencing was performed on a HiSeq4000 instrument (Illumina) using a single-end 50 bp run. Gene set analyses were run through cpdb.molgen.mpg.de gene set enrichment database.

Outcomes

The co-primary end-points were of safety and efficacy, judged respectively on the occurrence of adverse events and serious adverse events as classified by the Medical Dictionary for Regulatory Activities (MedDRA), and change in PVR (PVR Δ) as measured by invasive haemodynamic assessment via a fluid-filled right heart catheter using cardiac output measured using the thermodilution technique as per standard techniques previously described [21]. Secondary safety and exploratory efficacy end-points included 6MWT distance as per American Thoracic Society guidelines, Borg Dyspnoea Scale, NT-proBNP, WHO functional class assessment, Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) assessment, analysis of flow cytometric peripheral blood leukocyte immunophenotyping and serum and plasma measurements of circulating cytokines IL-1β, IL-6, IL-8 and TNF-α. A full description of the study schedule is included in the supplementary material. Post hoc descriptive statistics of secondary end-points and disease subtype were pre-specified in the statistical analysis plan.

Statistical analysis

The sample size (n) powered to detect a 30% reduction in PVR after 6 months of treatment with 90% power and 5% statistical significance was n=17, accounting for a conservative drop-out rate; the minimum target for recruitment was n=21 as published [19]. We present data on modified intention to treat (mITT), defined as the set of patients who have had at least one dose of tocilizumab and at least one post-baseline result, and an intention-to-treat (ITT) analysis as a sensitivity analysis, i.e. to assess the existence of potential bias and check that it did not differ from the mITT. Estimates of treatment response rate and associated confidence intervals (or credible intervals and posterior probabilities) are reported. The exception to this is the Wilcoxon signed rank test that was carried out on the PVR fold change as defined in the protocol paper [19]. An additional Bayesian analysis, considered to be more informative of the treatment response of PVR to tocilizumab, was pre-specified using an expert-elicited prior. Any predictor effects on secondary outcomes are reported with confidence intervals. All analyses reported here were performed using the R-Project (version 3.3.3; www.r-project.org). Principal component (PC) analyses of the RNAseq dataset, t-test with Benjamini–Hochberg procedure/false discovery rate (FDR) and penalised regression model (LASSO) using all immunophenotyping variables (cytokines, flow cytometric subsets and RNAseq) as predictors and assessing predictability of response performed best on cross-validation were all undertaken using the R-Project, as were Kaplan–Meier plots.

Mendelian randomisation

The association of a genetic variant in IL6R, rs7529229, with circulating levels of IL-6R was tested in European patients with idiopathic/heritable PAH recruited at Hammersmith Hospital, London, UK. Genotyping were performed through whole genome sequencing in the National Institute for Health Research BioResource study on Rare Diseases (NIHRBR) [22, 23]. Protein measurements were performed through aptamer-based proteomics [24]. The analysis was done with an additive model using natural logarithmic-transformed levels of circulating IL-6R followed by residualisation for age at sampling, gender and population structure (PC1–4) using SNPTEST [25]. The IL-6R protein level association estimate for rs7529229 in patients with idiopathic/heritable PAH was meta-analysed with estimates from two European population-based studies, which applied comparable methodologies [26, 27], using an inverse variance-weighted fixed-effects meta-analysis [28]. A two-sample MR analysis was performed on the meta-analysed estimate for IL6R at rs7529229 and accumulated genetic data from international consortia on four idiopathic/heritable PAH­–control comparisons [23]. The causal effect and its standard error were estimated using the Wald ratio as implemented in MR-Base [29]. When rs7529229 was not called in the case–control studies, we used a proxy, rs4537545, in high linkage disequilibrium (r2=0.99 in European individuals, run through ldlink.nci.nih.gov).

Survival analysis

Association of the genetic variant in IL6R, rs7529229, with all-cause mortality in idiopathic/heritable PAH patients of the NIHRBR study was used for Kaplan–Meier analysis. Survival analyses were left-truncated for time between diagnosis of PAH and sampling for genotyping.

Results

29 patients (male/female 10/19; mean±sd age 54.9±11.4 years) were recruited between January 2016 and April 2017. Of these, 15 patients had idiopathic PAH, 10 had CTD-associated PAH (nine scleroderma, one Sjögren's-associated PAH) and four had heritable PAH (table 1). Six patients were withdrawn prior to drug administration; one owing to a chest infection, one owing to an exacerbation of comorbid disease and four at baseline right heart catheterisation owing to discordant results with the last previous haemodynamic parameters, which the clinician judged non-stable disease as per entry criteria. In total, 23 patients received the study drug (figure 1).

View this table:
  • View inline
  • View popup
TABLE 1

Baseline demographics

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Consort diagram of phase 2 open-label study of tocilizumab. Consort diagram including intention-to-treat (ITT) and modified intention-to-treat (mITT) populations. RHC: right heart catheterisation.

The drug was discontinued in an additional four patients owing to serious adverse events (figure 1): one urosepsis, one chest pain, one peripheral arterial embolus and one suspected clinical deterioration event that did not fulfil pre-specified protocol criteria for a clinical worsening event on independent adjudication. Vomiting occurred in one patient and was classified as a suspected unexpected serious adverse reaction. There were no deaths. The most common adverse event was nasopharyngitis (figure 2). Adverse events were graded mild (80.0%), moderate (16.6%) and severe (3.4%).

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Medical Dictionary for Regulatory Activities (MedDRA)-coded common adverse events. Absolute numbers of MEDRA-coded most common adverse events. RTI: respiratory tract infection.

Overall, tocilizumab led to no significant change in PVR from baseline after 6 months of treatment in either the ITT or mITT analysis (figure 3a, b). In a priori analyses of PVR stratified by aetiology, four of the six CTD-associated PAH patients receiving study drug had a >15% reduction in PVR versus three of 13 patients with idiopathic or heritable PAH (figure 3c).

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Co-primary end-point; intention-to-treat (ITT) pulmonary vascular resistance (PVR) at baseline and end of study (EOS) in a) all patients (absolute values), b) Bayesian analysis of modified ITT (mITT) and c) mITT percentage change (PVR Δ) by disease group. CTD: connective tissue disease; I/FPAH: idiopathic/familial pulmonary arterial hypertension.

Bayesian analysis led to the same conclusion as the frequentist analysis (figure 3b). The expert-elicited prior was combined with the observed data to produce a posterior density for the probability of the study drug achieving a PVR change of at least −30%. The posterior probability of the study drug being successful was <1%.

Exploratory secondary end-point analyses were consistent with the primary end-point in that no secondary end-point data clearly supported a treatment effect (table 2). 6MWT distance increased by a mean±sd of 19.1±60.8 m, NT-proBNP increased by a median of 22.5 pg·mL−1 (IQR 275 pg·mL−1) and CAMPHOR decreased by median of 2 (IQR 10). WHO functional class changed in six patients, improving in four patients and deteriorating in two.

View this table:
  • View inline
  • View popup
TABLE 2

Secondary end-points

Consistent with effective inhibition of IL-6 signalling, tocilizumab exposure increased plasma IL-6 by a median of 9.5 pg·mL−1 (IQR 7.3 pg·mL−1) and CRP decreased by a median of 1.2 mg·L−1 (IQR 2.2 mg·L−1) (table 2 and supplementary figure S1). Plasma levels of IL-1β, IL-8 and TNF-α did not change (supplementary figure S1). In addition, immunophenotyping of peripheral blood cells did not show any significant changes in either B- or T-cell populations (supplementary figure S2). In RNAseq analyses there were no significant single gene expression changes after correction for multiple comparisons in response to tocilizumab. Network analyses of gene set over-representation and ontological analyses demonstrated changes in immune-mediated processes (supplementary table S1). Enriched protein complex-based sets were also dominated by signals associated with T- and B-cell-mediated immunity, notably the B-cell receptor (supplementary table S2).

PC analyses of RNAseq gene expression and expression changes did not discriminate either CTD-associated PAH or the potential responders in the cohort (t-test, Benjamini–Hochberg procedure with FDR<0.1) (supplementary figure S3). Overall, none of the immunophenotyping data correlated with treatment response or predicted responders from non-responders either individually or using integrative modelling. Consistent with a treatment effect on gene expression, in PC analysis there was modest evidence that pre- and post-treatment categorisation could be differentiated in two dimensions on the basis of the first two PCs (Peacock test, p=0.033). In a penalised regression model (LASSO) using all immunophenotyping variables as predictors and assessing predictability of response, the model performed best on cross-validation when no variables were included in the predictive model (supplementary figure S4). Therefore, there was no additional value added by analyses that utilised all of the inflammatory dataset, and no inflammatory marker predicted treatment response either individually or in combinatorial modelling.

In an association analysis, each minor allele, “C”, at rs7529229 was associated with an increase in circulating IL-6R level in 124 patients with idiopathic or heritable PAH (effect estimate 0.27±0.03, p=2.69×10−16, figure 4c). A meta-analysis including these PAH patients and an additional 4299 individuals from two population-based cohorts revealed an overall effect estimate of 0.81±0.01 per “C” allele (OR 2.1, p<1×10−300) but no trans-acting locus associated with circulating IL-6R (figure 4a, b). MR revealed no significant association of rs7529229 with risk of PAH in our pooled analyses of 2085 cases with idiopathic or heritable PAH and 9659 controls (OR 0.99, 95% CI 0.9–1.09, p=0.88, figure 4e). In addition, genotype at IL6R SNP rs7529229 was not associated with all-cause mortality in the NIHRBR study cohort (figure 4d).

FIGURE 4
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4

Mendelian randomisation of interleukin-6 receptor (IL-6R) in idiopathic pulmonary arterial hypertension (PAH). a) Protein quantitative trait locus (pQTL) in genome-wide association studies. b) Locus zoom of pQTL. c) Circulating IL-6R levels performed through aptamer-based protein measurements by genotype of IL6R single nucleotide polymorphism (SNP) rs7529229 (T/T, T/C and minor allele C/C) in UK patients with familial/idiopathic PAH. d) Left-truncated Kaplan–Meier plots for patients with PAH stratified by IL6R SNP rs7529229 in the UK National Institute for Health Research BioResource Rare Diseases study (NIHRBR) study cohort. e) Forest plot meta-analyses of association IL6R lead SNP association with familial/idiopathic PAH in international studies. PAHB: US National Biological Sample and Data Repository for Pulmonary Arterial Hypertension (also known as PAH Biobank); PHAAR: Pulmonary Hypertension Allele-Associated Risk study; BHFPAH: British Heart Foundation Pulmonary Arterial Hypertension study.

Discussion

This proof-of-concept open-label clinical trial demonstrated no significant effect of tocilizumab in prevalent group 1 PAH. This was despite evidence that the drug led to expected changes in biomarkers of target engagement: increased IL-6 and decreased CRP levels. In addition, B- and T-cell activation pathways were the top ontology hits in RNAseq analysis. It is possible that the stable prevalent patients recruited to this study were less likely to have active inflammation, although the IL-6 and CRP levels measured are in line with previous reports [8].

The lack of efficacy in this trial would seem to contradict the extensive data in preclinical cell and animal models for an important potentially causal role for IL-6. There are a number of explanations for this. It is possible that inflammation is a response to vascular injury rather than a causal factor in human PAH, though in MR studies we did not see an association with disease course based on mortality. It is notable that in PAH cohorts the IL-6 levels are skewed with a non-normal distribution and the majority of patients do not have significantly higher levels [8]. This raises the possibility that disease is driven by inflammation only in a subset of patients, or that there are flares of inflammatory activity in patients. Meta-analyses of autoimmune phase 3 trials stratified by IL-6 demonstrate disappointing correlations with clinical response [30] and this approach is not recommended in any of the current indications for IL-6 receptor antagonism. Our planned sub-analyses of response using extensive inflammatory markers, including IL-6, suggest again that stratifying patients by IL-6 levels would not have been of additional value. We note that in our original report, IL-6 levels were almost double those reported here [8]. Though no trial has strongly suggested stratification by IL-6 works in other diseases, this may reflect a random sampling bias, the effect of targeted therapies, differences in assays or the requirements for stable disease, which one can hypothesise negatively selects against patients with active inflammation.

Our entry criteria for CTD-associated PAH excluded specific, less common autoimmune patient groups with RA, SLE and mixed CTD. The reasons for exclusion included that these patients are already receiving immunosuppression and it was not felt appropriate from a safety perspective for a first trial of immunosuppression to include subsets of patients on multiple therapies. In addition, this would have led to greater heterogeneity in the patient cohort. Despite this, there was a reduction in PVR in four of six patients with CTD-associated PAH. Immunosuppression is widely used in the context of CTD but at present the effects on the associated PAH have not been investigated in randomised controlled trials. Based on the limited data presented here, it may be advisable to prioritise future trials of immunosuppression in CTD-associated PAH. This will be complicated by the heterogeneous nature of both the patient population and the use of immunosuppressive agents in some patients prior to the onset of PAH. Such trials would need to consider the mixed disease population and mixed background of immunosuppressive drugs carefully.

Potential limitations of our experimental study are the small size and open-label design. In addition, it is possible that the impact of immunosuppression on PVR, if present, could take longer than 6 months. Previous meta-analyses have demonstrated that PVR is not a placebo-responsive end-point [19]. This is supported by our trial results. In previous trials of a similar duration, PVR was more likely to deteriorate in placebo arms and it is therefore possible that we have missed a difference between active drug and placebo, had we included one. Nevertheless, this difference would by definition have been small and of limited clinical utility in the context of the additional risk patients are exposed to by immunosuppression.

This is the first time in PAH where genetic data have been used in tandem to test drug target validity in combination with early phase go/no-go investigator-led clinical trials. Our association analysis results confirm that rs7529229 associates with circulating IL-6R levels, as anticipated. However, there was no significant association between that variant and the presence or absence of PAH, providing additional evidence that modulation of IL-6 signalling may not be of benefit for most PAH patients. If the approach of leveraging genetic data in evaluating therapies gains traction, the possible signal in CTD/scleroderma is potentially supported by existing meta-analyses data in scleroderma not stratified by presence of PAH, where STAT3 emerges as a risk loci [31]. Such approaches will be a potentially useful addition to the toolkit for drug development. Coupling fast and statistically efficient trial designs to MR studies is feasible even in rare disease, where co-operative international genetics consortia are making open access genomic data a reality in numbers robust enough to test hypotheses. We acknowledge that our MR meta-analyses are not powered to pick up smaller effects and this still cannot be ruled out.

In summary, treatment with tocilizumab is feasible in PAH but demonstrated no significant effects on haemodynamic parameters or exploratory secondary end-points in heritable or idiopathic PAH. MR studies were in line with these results. A potential improvement was noted in the small subgroup of patients with CTD-associated PAH and this warrants further investigation. Future trials in immunomodulation in PAH need to consider whether endotyping and stratification of patients earlier in the disease process might be worthwhile.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary material ERJ-02463-2020.Supplement

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-02463-2020.Shareable

Acknowledgements

A full list of collaborators is included in the supplementary material.

Footnotes

  • TRANSFORM-UK, ClinicalTrials.gov number NCT02676947. Individual de-identified primary and secondary end-point data will be made available with a data dictionary. The study protocol and statistical analysis plan are publicly available and published. Data will be available on publication. Data will be hosted on University of Cambridge open access repository.

  • Conflict of interest: M. Toshner reports grants and personal fees from Bayer and Actelion, and personal fees from MSD and GSK, during the conduct of the study, and serves on the advisory board for MorphogenIX.

  • Conflict of interest: C. Church has received travel grants and speaker fees from GSK, Actelion and Bayer.

  • Conflict of interest: L. Harbaum has nothing to disclose.

  • Conflict of interest: C. Rhodes reports personal fees for advisory board work from Actelion and United Therapeutics, outside the submitted work.

  • Conflict of interest: S.S. Villar Moreschi has nothing to disclose.

  • Conflict of interest: J. Liley has nothing to disclose.

  • Conflict of interest: R. Jones has nothing to disclose.

  • Conflict of interest: A. Arora has nothing to disclose.

  • Conflict of interest: K. Batai has nothing to disclose.

  • Conflict of interest: A.A. Desai has nothing to disclose.

  • Conflict of interest: J.G. Coghlan reports research support, consultancy fees and speaker honoraria from Actelion.

  • Conflict of interest: J.S.R. Gibbs reports personal fees from Acceleron, Arena, Bayer, Bellepheron, Complexa, Pfizer and United Therapeutics, grants and personal fees from Actelion, and personal fees and non-financial support from GSK, outside the submitted work.

  • Conflict of interest: D. Gor was an employee of Roche, during the conduct of the study.

  • Conflict of interest: S. Gräf has nothing to disclose.

  • Conflict of interest: L. Harlow has nothing to disclose.

  • Conflict of interest: J. Hernandez-Sanchez is an employee of Roche but was not at the time of trial conduct.

  • Conflict of interest: L.S. Howard has received personal fees and institutional grants/research support from Bayer and personal fees from MSD, Daichii Sayo and Pfizer.

  • Conflict of interest: M. Humbert has received personal fees from Actelion, Merck and United Therapeutics, and grants and personal fees from Bayer and GSK.

  • Conflict of interest: J. Karnes has nothing to disclose.

  • Conflict of interest: D.G. Kiely reports grants and personal fees from Bayer and Actelion, and personal fees from GSK and MSD, during the conduct of the study.

  • Conflict of interest: R. Kittles has nothing to disclose.

  • Conflict of interest: E. Knightbridge has nothing to disclose.

  • Conflict of interest: B. Lam has nothing to disclose.

  • Conflict of interest: K.A. Lutz has nothing to disclose.

  • Conflict of interest: W.C. Nichols has nothing to disclose.

  • Conflict of interest: M.W. Pauciulo has nothing to disclose.

  • Conflict of interest: J. Pepke-Zaba has served on advisory boards of and received personal fees and institutional grant/research support from Actelion, Bayer, MSD and GSK.

  • Conflict of interest: J. Suntharalingam has nothing to disclose.

  • Conflict of interest: F. Soubrier has nothing to disclose.

  • Conflict of interest: R.C. Trembath has nothing to disclose.

  • Conflict of interest: T-H.L. Schwantes-An has nothing to disclose.

  • Conflict of interest: S.J. Wort reports grants and personal fees from Actelion and Bayer, and personal fees from GSK and MSD, outside the submitted work.

  • Conflict of interest: M.R. Wilkins has nothing to disclose.

  • Conflict of interest: S. Gaine has received honoraria from Actelion and United Therapeutics; has received travel grants from Actelion, Novartis and Menerini; and has performed drug safety board monitoring for United Therapeutics, GSK and Novartis.

  • Conflict of interest: N.W. Morrell reports personal fees from MorphogenIX, during the conduct of the study.

  • Conflict of interest: P.A. Corris has served on speakers’ bureau and advisory boards of Actelion, Bayer and MSD, and received institutional grant/research support from Actelion and Bayer.

  • Support statement: This work was funded by a grant from the UK National Institute of Health Research Cambridge Biomedical Research Centre and Rare Diseases Translational Research Collaboration, in addition to an unrestricted grant from Roche Products Limited, Welwyn Garden City, UK. TRANSFORM-UK, ClinicalTrials.gov number NCT02676947. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received June 23, 2020.
  • Accepted July 15, 2021.
  • Copyright ©The authors 2022.
http://creativecommons.org/licenses/by/4.0/

This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.

References

  1. ↵
    1. Simonneau G,
    2. Galie N,
    3. Rubin LJ, et al.
    Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S–12S. doi:10.1016/j.jacc.2004.02.037
    OpenUrlFREE Full Text
  2. ↵
    1. Mouthon L,
    2. Guillevin L,
    3. Humbert M
    . Pulmonary arterial hypertension: an autoimmune disease? Eur Respir J 2005; 26: 986–988. doi:10.1183/09031936.05.00112105
    OpenUrlFREE Full Text
  3. ↵
    1. Dweik RA,
    2. Rounds S,
    3. Erzurum SC, et al.
    An official American Thoracic Society statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med 2014; 189: 345–355. doi:10.1164/rccm.201311-1954ST
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Morse JH,
    2. Antohi S,
    3. Kasturi K, et al.
    Fine specificity of anti-fibrillin-1 autoantibodies in primary pulmonary hypertension syndrome. Scand J Immunol 2000; 51: 607–611. doi:10.1046/j.1365-3083.2000.00733.x
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Huertas A,
    2. Phan C,
    3. Bordenave J, et al.
    Regulatory T cell dysfunction in idiopathic, heritable and connective tissue-associated pulmonary arterial hypertension. Chest 2016; 149: 1482–1493. doi:10.1016/j.chest.2016.01.004
    OpenUrl
  6. ↵
    1. Ulrich S,
    2. Taraseviciene-Stewart L,
    3. Huber LC, et al.
    Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study. Respir Res 2008; 9: 20. doi:10.1186/1465-9921-9-20
    OpenUrlCrossRefPubMed
  7. ↵
    1. Hassoun PM,
    2. Mouthon L,
    3. Barbera JA, et al.
    Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: S10–S19. doi:10.1016/j.jacc.2009.04.006
    OpenUrlFREE Full Text
  8. ↵
    1. Soon E,
    2. Holmes AM,
    3. Treacy CM, et al.
    Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010; 122: 920–927. doi:10.1161/CIRCULATIONAHA.109.933762
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Stahl EA,
    2. Raychaudhuri S,
    3. Remmers EF, et al.
    Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42: 508–514. doi:10.1038/ng.582
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Steiner MK,
    2. Syrkina OL,
    3. Kolliputi N, et al.
    Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009; 104: 236–244. doi:10.1161/CIRCRESAHA.108.182014
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Savale L,
    2. Tu L,
    3. Rideau D, et al.
    Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 2009; 10: 6. doi:10.1186/1465-9921-10-6
    OpenUrlCrossRefPubMed
  12. ↵
    1. Miyata M,
    2. Sakuma F,
    3. Yoshimura A, et al.
    Pulmonary hypertension in rats. 2: role of interleukin-6. Int Arch Allergy Immunol 1995; 108: 287–291. doi:10.1159/000237166
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Alten R,
    2. Maleitzke T
    . Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med 2013; 45: 357–363. doi:10.3109/07853890.2013.771986
    OpenUrlCrossRefPubMed
  14. ↵
    1. Elhai M,
    2. Meunier M,
    3. Matucci-Cerinic M, et al.
    Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013; 72: 1217–1220. doi:10.1136/annrheumdis-2012-202657
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Tamura Y,
    2. Phan C,
    3. Tu L, et al.
    Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. J Clin Invest 2018; 128: 1956–1970. doi:10.1172/JCI96462
    OpenUrlCrossRef
  16. ↵
    1. Arita Y,
    2. Sakata Y,
    3. Sudo T, et al.
    The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease. Heart Vessels 2010; 25: 444–447. doi:10.1007/s00380-009-1215-5
    OpenUrlPubMed
  17. ↵
    1. Furuya Y,
    2. Satoh T,
    3. Kuwana M
    . Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol 2010; 2010: 720305. doi:10.1155/2010/720305
    OpenUrlPubMed
  18. ↵
    1. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R) Consortium,
    2. Swerdlow DI,
    3. Holmes MV, et al.
    The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379: 1214–1224. doi:10.1016/S0140-6736(12)60110-X
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Hernandez-Sanchez J,
    2. Harlow L,
    3. Church C, et al.
    Clinical trial protocol for TRANSFORM-UK: a therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. Pulm Circ 2018; 8: 2045893217735820. doi:10.1177/2045893217735820
    OpenUrl
  20. ↵
    1. Maecker HT,
    2. McCoy JP,
    3. Nussenblatt R
    . Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol 2012; 12: 191–200. doi:10.1038/nri3158
    OpenUrlCrossRefPubMed
  21. ↵
    1. Suntharalingam J,
    2. Treacy CM,
    3. Doughty NJ, et al.
    Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008; 134: 229–236. doi:10.1378/chest.07-2681
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Rhodes CJ,
    2. Batai K,
    3. Bleda M, et al.
    Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir Med 2019; 7: 227–238. doi:10.1016/S2213-2600(18)30409-0
    OpenUrl
  23. ↵
    1. Rhodes CJ,
    2. Wharton J,
    3. Ghataorhe P, et al.
    Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respir Med 2017; 5: 717–726. doi:10.1016/S2213-2600(17)30161-3
    OpenUrl
  24. ↵
    1. Marchini J,
    2. Howie B,
    3. Myers S, et al.
    A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007; 39: 906–913. doi:10.1038/ng2088
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Suhre K,
    2. Arnold M,
    3. Bhagwat AM, et al.
    Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun 2017; 8: 14357. doi:10.1038/ncomms14357
    OpenUrlCrossRefPubMed
  26. ↵
    1. Sun BB,
    2. Maranville JC,
    3. Peters JE, et al.
    Genomic atlas of the human plasma proteome. Nature 2018; 558: 73–79. doi:10.1038/s41586-018-0175-2
    OpenUrlCrossRefPubMed
  27. ↵
    1. Magi R,
    2. Morris AP
    . GWAMA: software for genome-wide association meta-analysis. BMC Bioinformatics 2010; 11: 288. doi:10.1186/1471-2105-11-288
    OpenUrlCrossRefPubMed
  28. ↵
    1. Lawlor DA,
    2. Harbord RM,
    3. Sterne JA, et al.
    Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27: 1133–1163. doi:10.1002/sim.3034
    OpenUrlCrossRefPubMed
  29. ↵
    1. Hemani G,
    2. Zheng J,
    3. Elsworth B, et al.
    The MR-Base platform supports systematic causal inference across the human phenome. eLife 2018; 7: e34408. doi:10.7554/eLife.34408
    OpenUrlCrossRefPubMed
  30. ↵
    1. Wang J,
    2. Platt A,
    3. Upmanyu R, et al.
    IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open 2013; 3: e003199.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. González-Serna D,
    2. Ochoa E,
    3. López-Isac E, et al.
    A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn's disease. Sci Rep 2020; 10: 1862. doi:10.1038/s41598-020-58741-w
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 59 Issue 3 Table of Contents
European Respiratory Journal: 59 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
Mark Toshner, Colin Church, Lars Harbaum, Christopher Rhodes, Sofia S. Villar Moreschi, James Liley, Rowena Jones, Amit Arora, Ken Batai, Ankit A. Desai, John G. Coghlan, J. Simon R. Gibbs, Dee Gor, Stefan Gräf, Louise Harlow, Jules Hernandez-Sanchez, Luke S. Howard, Marc Humbert, Jason Karnes, David G. Kiely, Rick Kittles, Emily Knightbridge, Brian Lam, Katie A. Lutz, William C. Nichols, Michael W. Pauciulo, Joanna Pepke-Zaba, Jay Suntharalingam, Florent Soubrier, Richard C. Trembath, Tae-Hwi L. Schwantes-An, S. John Wort, Martin R. Wilkins, Sean Gaine, Nicholas W. Morrell, Paul A. Corris
European Respiratory Journal Mar 2022, 59 (3) 2002463; DOI: 10.1183/13993003.02463-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
Mark Toshner, Colin Church, Lars Harbaum, Christopher Rhodes, Sofia S. Villar Moreschi, James Liley, Rowena Jones, Amit Arora, Ken Batai, Ankit A. Desai, John G. Coghlan, J. Simon R. Gibbs, Dee Gor, Stefan Gräf, Louise Harlow, Jules Hernandez-Sanchez, Luke S. Howard, Marc Humbert, Jason Karnes, David G. Kiely, Rick Kittles, Emily Knightbridge, Brian Lam, Katie A. Lutz, William C. Nichols, Michael W. Pauciulo, Joanna Pepke-Zaba, Jay Suntharalingam, Florent Soubrier, Richard C. Trembath, Tae-Hwi L. Schwantes-An, S. John Wort, Martin R. Wilkins, Sean Gaine, Nicholas W. Morrell, Paul A. Corris
European Respiratory Journal Mar 2022, 59 (3) 2002463; DOI: 10.1183/13993003.02463-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Genetics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Research Articles

  • Decreased carnitine metabolism independent of oral corticosteroid treatment in asthma
  • Validation of a refined 4-stratum risk assessment score for PH
  • Lung transplantation for acute respiratory distress syndrome
Show more Original Research Articles

Pulmonary hypertension and genetics

  • Pulmonary arterial hypertension patients carrying a TBX4 mutation
Show more Pulmonary hypertension and genetics

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society